2021
DOI: 10.1200/jco.20.01691 View full text |Buy / Rent full text
|
|

Abstract: PURPOSE Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin. METHODS In a phase III, US intergroup… Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
1
6
0

Publication Types

Select...

Relationship

0
0

Authors

Journals